New antibody combo shows promise in early cancer trial

NCT ID NCT04752826

Recruiting now Disease control Sponsor: BioInvent International AB Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 176 participants whose cancer has worsened after standard treatments will receive infusions every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI-1808 (an experimental antibody) and pembrolizumab (Keytruda, an immunotherapy drug)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is an early, first-in-human trial with a small number of participants, so safety and effectiveness are not yet proven. There is a risk of side effects, and the drug may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer fallopian tube cancer melanoma neoplasm ovarian cancer peritoneum cancer T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCIES MELANOMA OVARIAN CANCER T-CELL LYMPHOMA

Contacts and locations

Locations

Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser
TERMINATED

Omsk, 644013, Russia
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
Debreceni Egyetem Klinikai Központ
WITHDRAWN

Debrecen, 4032, Hungary
Guy's and Saint Thomas' NHS Foundation Trust
RECRUITING

London, SE1 9RT, United Kingdom
Herlev Hospital
RECRUITING

Herlev, 2730, Denmark
Hospital General Universitario Gregorio Marañon
RECRUITING

Madrid, 28007, Spain
Hospital Universitario 12 de Octubre
NOT_YET_RECRUITING

Madrid, 28041, Spain
Institut Catala d'oncologia. Hospital Duran I Reynals
NOT_YET_RECRUITING

Barcelona, 08907, Spain
Karolinska University Hospital, Solna
RECRUITING

Stockholm, 17176, Sweden
Magyar Honvédség-Egészségügyi Központ
RECRUITING

Budapest, 1134, Hungary
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
N.N. Petrov National Medical Research Center of Oncology
WITHDRAWN

Saint Petersburg, 197758, Russia
National Medical Research Center VA Almazov
WITHDRAWN

Saint Petersburg, 197022, Russia
PRA Health Sciences - Hungary
ACTIVE_NOT_RECRUITING

Budapest, 1077, Hungary
Rigshospitalet
RECRUITING

Copenhagen, Denmark
START Madrid - Hospital Universitario Fundación Jiménez Díaz
RECRUITING

Madrid, 28040, Spain
Sahlgrenska University Hospital
RECRUITING

Gothenburg, 41345, Sweden
Sarah Cannon Research Institute UK
RECRUITING

London, W1G 6AD, United Kingdom
Skanes University Hospital
RECRUITING

Lund, 223 70, Sweden
Southampton General Hospital
RECRUITING

Southampton, SO16 6YD, United Kingdom
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
The Royal Marsden Hospital NHS Foundation Trust
RECRUITING

London, United Kingdom
University Hospital Birmingham
RECRUITING

Birmingham, United Kingdom
University Hospitals of Leicester NHS Trust
RECRUITING

Leicester, LE1 5WW, United Kingdom
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.